Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Saussine, Anne ^a,b,c   Tazi, Abdellatif ^b   Feuillet, Séverine ^b   Rybojad, Michel ^c   Juillard, Caroline ^c   Bergeron, Anne ^b   Dessirier, Valérie ^a,b   Bouhidel, Fatiha ^b,c   Janin, Anne ^b,c   Bensussan, Armand ^a,b   Bagot, Martine ^a,b,c   Bouaziz, Jean David ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 10;

ADULT; ARTICLE; B LYMPHOCYTE; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HYPERGAMMAGLOBULINEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SARCOIDOSIS; SKIN GRANULOMA;

ADOLESCENT; ADULT; AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES, REGULATORY; CASE-CONTROL STUDIES; CELL COUNT; CHRONIC DISEASE; FEMALE; GRANULOMA; HUMANS; HYPERGAMMAGLOBULINEMIA; INTERLEUKIN-10; MALE; MIDDLE AGED; PHENOTYPE; SARCOIDOSIS; TIME FACTORS; YOUNG ADULT;

EID: 84865190333     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043588     Document Type: Article

References (37)

1. Iannuzzi MC, Rybicki BA, Teirstein AS, ((2007)) Sarcoidosis. N Engl J Med 357:: 2153--2165 doi: 10.1056/NEJMra071714.
2. Bäumer I, Zissel G, Schlaak M, Müller-Quernheim J, ((1997)) Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 16:: 171--177.
3. Bergeron A, Bonay M, Kambouchner M, Lecossier D, Riquet M, et al. ((1997)) Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J Immunol 159:: 3034--3043.
4. Zissel G, Prasse A, Müller-Quernheim J, ((2010)) Immunologic response of sarcoidosis. Semin Respir Crit Care Med 31:: 390--403 doi: 10.1055/s-0030-1262208.
5. Hunninghake GW, Crystal RG, ((1981)) Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest 67:: 86--92 doi: 10.1172/JCI110036.
6. Fazel SB, Howie SE, Krajewski AS, Lamb D, ((1992)) B lymphocyte accumulations in human pulmonary sarcoidosis. Thorax 47:: 964--967.
7. Belkhou A, Younsi R, El Bouchti I, El Hassani S, ((2008)) Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 75:: 511--512 doi: 10.1016/j.jbspin.2008.01.025.
8. Dasilva V, Breuil V, Chevallier P, Euller-Ziegler L, ((2010)) Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine 77:: 82--83 doi: 10.1016/j.jbspin.2009.11.005.
9. Gottenberg J-E, Guillevin L, Lambotte O, Combe B, Allanore Y, et al. ((2005)) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:: 913--920 doi: 10.1136/ard.2004.029694.
10. Yanaba K, Bouaziz J-D, Matsushita T, Magro CM, St Clair EW, et al. ((2008)) B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:: 284--299 doi: 10.1111/j.1600-065X.2008.00646.x.
11. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, et al. ((2010)) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32:: 129--140 doi: 10.1016/j.immuni.2009.11.009.
12. Bouaziz J-D, Yanaba K, Venturi GM, Wang Y, Tisch RM, et al. ((2007)) Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 104:: 20878--20883 doi: 10.1073/pnas.0709205105.
13. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, et al. ((2007)) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178:: 6092--6099.
14. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM, ((2002)) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:: 944--950 doi: 10.1038/ni833.
15. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, et al. ((2011)) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117:: 530--541 doi: 10.1182/blood-2010-07-294249.
16. Mauri C, Gray D, Mushtaq N, Londei M, ((2003)) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197:: 489--501.
17. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK, ((1997)) Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 186:: 1749--1756.
18. Wolf SD, Dittel BN, Hardardottir F, Janeway CA, ((1996)) Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 184:: 2271--2278.
19. Bouaziz J-D, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, et al. (2010) IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol. Available:http://www.ncbi.nlm.nih.gov/pubmed/20809522. Accessed 12 October 2010.
20. Mackay F, Browning JL, ((2002)) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:: 465--475 doi: 10.1038/nri844.
21. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, et al. ((2006)) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:: 192--201 doi: 10.1002/art.21526.
22. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, et al. ((2001)) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:: 6--10.
23. Medoff BD, Thomas SY, Banerji A, Wain JC, Zhang H, et al. ((2005)) Pathogenic T-cell recruitment into the airway in human disease. Ann N Y Acad Sci 1062:: 220--241 doi: 10.1196/annals.1358.026.
24. Quismorio FP Jr, Sharma OP, Chandor S, ((1977)) Immunopathological studies on the cutaneous lesions in sarcoidosis. Br J Dermatol 97:: 635--642.
25. Bouaziz J-D, Yanaba K, Tedder TF, ((2008)) Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224:: 201--214 doi: 10.1111/j.1600-065X.2008.00661.x.
26. Bouaziz J-D, Le Buanec H, Saussine A, Bensussan A, Bagot M (2012) IL-10 producing regulatory B cells in mice and humans: state of the art. Current Molecular Medicine. Available:http://www.ncbi.nlm.nih.gov/pubmed/22292445. Accessed 5 February 2012.
27. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44: 1313-1319. doi: 10.1002/1529-0131(200106)44:6&1313::AID-ART223>3.0.CO;2-S.
28. Lee N-S, Barber L, Akula SM, Sigounas G, Kataria YP, et al. ((2011)) Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol 18:: 1306--1316 doi: 10.1128/CVI.05118-11.
29. Landolt-Marticorena C, Wither R, Reich H, Herzenberg A, Scholey J, et al. ((2011)) Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J Rheumatol 38:: 642--651 doi: 10.3899/jrheum.100214.
30. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, et al. ((2006)) The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 203:: 359--370 doi: 10.1084/jem.20050648.
31. Wahlström J, Katchar K, Wigzell H, Olerup O, Eklund A, et al. ((2001)) Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 163:: 115--121.
32. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, et al. ((2000)) Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192:: 953--964.
33. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, et al. ((2011)) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:: 721--731 doi: 10.1016/S0140-6736(10)61354-2.
34. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999 ((1999)) Am J Respir Crit Care Med. 160:: 736--755.
35. Boudouin SV, du Bois RM. (1994) Disease activity. In: James DG, ed. Sarcoidosis and other granulomatous disorders. New York, NY: Marcel Dekker, 573-595.
36. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993 ((1994)) Eur Respir J. 7:: 624--627.
37. Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Vérola O, et al. ((1998)) Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:: 370--374.